Holen Sie sich die Stockscreener-App
16.44
2.24%
0.36
Vorhandelsmarkt:
16.70
0.26
+1.58%
Schlusskurs vom Vortag:
$16.08
Offen:
$16.15
24-Stunden-Volumen:
1.33M
Relative Volume:
0.63
Marktkapitalisierung:
$2.53B
Einnahmen:
$205.22M
Nettoeinkommen (Verlust:
$-121.24M
KGV:
-20.19
EPS:
-0.8141
Netto-Cashflow:
$-82.81M
1W Leistung:
+1.42%
1M Leistung:
-4.97%
6M Leistung:
+26.27%
1J Leistung:
+102.46%
1-Tages-Spanne:
$16.15
$16.95
1-Wochen-Bereich:
$15.11
$16.95
52-Wochen-Spanne:
$6.255
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
16.44 | 2.47B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Amova Asset Management Americas Inc. Decreases Stake in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Insider Sell: Harlan Robins Sells 24,233 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 10,000 Shares - MarketBeat
Adaptive Biotechnologies CSO Robins sells $392,329 in ADPT stock - Investing.com Australia
Chad Robins Sells 289,024 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $823,848.16 in Stock - MarketBeat
Insider Sell: Chad Robins Sells 524,998 Shares of Adaptive Biote - GuruFocus
CEO of Adaptive Biotechnologies (NASDAQ: ADPT) sells 524,998 shares - Stock Titan
Adaptive Biotechnologies CEO Sells Over $8 Million in Company Stock - TradingView
A Look At Adaptive Biotechnologies (ADPT) Valuation As CEO Updates MRD Growth And Profitability Outlook - simplywall.st
Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Unveiling a 29% Upside Potential for Savvy Investors - DirectorsTalk Interviews
Adaptive Biotechnologies CEO Flags MRD Momentum, Lifts 2025 Volume Outlook to 30%+ at TD Cowen Conf. - Yahoo Finance
Adaptive Biotechnologies at TD Cowen Conference: Strategic Growth Insights - Investing.com
[144] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
Chad Robins files Form 144 to sell ADPT shares (ADPT) - Stock Titan
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Adaptive Biotechnologies2026 Funding Rounds & List of Investors - Tracxn
Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)? - Yahoo Finance
Chad M. Robins files multiple Rule 144 notices for ADPT (ADPT) - Stock Titan
Decoding Adaptive Biotechnologies Corp (ADPT): A Strategic SWOT Insight - GuruFocus
Adaptive Biotechnologies (NASDAQ: ADPT) posts 2025 MRD-driven surge - Stock Titan
Does Post‑Earnings Analyst Optimism Around clonoSEQ Adoption Change The Bull Case For Adaptive (ADPT)? - simplywall.st
TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT) - Finviz
ADPT Technical Analysis & ETF Price Forecast - Intellectia AI
Principal Financial Group Inc. Sells 303,285 Shares of Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Buy Signal: What is the earnings history of EUDAW2025 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Allianz Asset Management GmbH Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells 2,145 Shares of Stock - MarketBeat
ADPT: BTIG Raises Price Target Following Analyst Update | ADPT S - GuruFocus
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $21.00 - MarketBeat
ADPT: JP Morgan Raises Price Target and Maintains Overweight Rat - GuruFocus
Adaptive Biotechnologies (ADPT) stock swings after earnings as MRD guidance, insider sale draw scrutiny - TechStock²
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth - Investing.com UK
Adaptive Biotechnologies Corp (ADPT) Q4 2025 Earnings Call Highl - GuruFocus
Adaptive Biotech (ADPT) Earnings Call Transcript - The Globe and Mail
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Adaptive Biotechnologies Q4 2025 slides: 55% revenue growth as MRD business expands - Investing.com
Adaptive Biotechnologies (ADPT) Sees Strong Revenue Growth and P - GuruFocus
Earnings call transcript: Adaptive Biotechnologies beats Q4 2025 expectations - Investing.com
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Adaptive Biotechnologies soars after beating Q4 expectations By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies soars after beating Q4 expectations - Investing.com
Adaptive Biotechnologies: Fourth Quarter Financial Highlights - Bitget
Adaptive Biotechnologies: Q4 Earnings Snapshot - KTVB
Adaptive Biotechnologies earnings beat by $0.09, revenue topped estimates - Investing.com
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):